secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2022-12-05T23:59:59+00:00
Accession:  0001493152-22-034460
Event type: leadership
Sentiment:  negative
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte CEO Ronald Andrews steps down; Joshua Riggs named Interim CEO, Louis Silverman appointed to board
--------------------------------------------------------------------------------

- Ronald Andrews resigns as President, CEO, and director, effective Dec 1, 2022.
- Joshua Riggs, previously General Manager Transplant, appointed Interim CEO effective Dec 2, 2022.
- Andrews receives severance: $500K cash, 12 months COBRA ($40,128), accelerated vesting of equity.
- Andrews to provide consulting services through Feb 28, 2023; receives stock options for 50,000 shares.
- Board appoints Louis Silverman as director; he is CEO of Hicuity Health, former CEO of Quality Systems.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315222034460/0001493152-22-034460-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315222034460/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-034460

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer